Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethaverine SCHEMBL29355739 | 1.00 | PDE3A (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL25606 | 1.00 | PDE3A (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL29624566 | 0.99 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL9614397 | 0.99 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL16180359 | 0.99 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL317507 | 0.99 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL30417501 | 0.99 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL17603566 | 0.99 | PDE3A (0.97) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| SCHEMBL2455134 | 0.93 | PDE3A (0.87) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| SCHEMBL2460329 | 0.91 | PDE3A (0.83) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024200612-A1 | INHIBITORS OF URIDINE CATABOLISM AND/OR TRANSPORT FOR THERAPY | Université de Lausanne (CH) | 2024-10-03 | — | — | WO | claimed |
| EP-3663366-B1 | USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS | SYMRISE AG (DE) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024197124-A9 | ARGININE VASOPRESSIN RECEPTOR (AVPR) ANTAGONISTS AND METHODS OF USING THEREOF | UNIVERSITY OF MIAMI (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4469439-A1 | NEW COOLANTS, AND PREPARATIONS CONTAINING SAME | Symrise AG (DE) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024200612-A1 | INHIBITORS OF URIDINE CATABOLISM AND/OR TRANSPORT FOR THERAPY | Université de Lausanne (CH) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024197124-A2 | ARGININE VASOPRESSIN RECEPTOR (AVPR) ANTAGONISTS AND METHODS OF USING THEREOF | UNIVERSITY OF MIAMI (US) | 2024-09-26 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-116897040-A | Compounds and methods for treating coronaviruses | APTEEUS公司 | 2023-10-17 | — | — | CN | disclosed |
| EP-4247791-A2 | NEW COOLANTS, AND PREPARATIONS CONTAINING SAME | Symrise AG (DE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3675809-B1 | USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS | BASF SE (DE) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023144326-A1 | NEW COOLANTS, AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023143741-A1 | NEW COOLANTS, AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2023-08-03 | — | — | WO | disclosed |
| CN-116507327-A | Chewable formulations | 礼蓝动物保健有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | disclosed |
| CN-114795402-A | Scoring balloon with translating score line | 巴德股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022106452-A2 | NEW COOLANTS, AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022105986-A1 | NOVEL COOLING AGENTS AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2022-05-27 | — | — | WO | disclosed |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | RICHTER GEDEON NYRT. (HU) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | AVPR1B, AVPR1A, AVPR2 | PDE3A 607/4885SMN1; SMN2 4312/4885CYP3A4 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.